2011-2012 - IRCM
2011-2012 - IRCM
2011-2012 - IRCM
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
American Society of Hypertension & Hypertension<br />
Canada), Alliston, Ontario<br />
Hypertension artérielle réfractaire, Forum en médecine<br />
familiale <strong>2011</strong>, Montréal, Québec<br />
La Société québécoise d’hypertension artérielle : 20 ans<br />
de réalisations… 1992-<strong>2012</strong> / Recherche Clinique, 20 e<br />
Réunion scientifique annuelle de la Société<br />
québécoise d’hypertension artérielle, Québec, Québec<br />
Thiazides : Bénéfices cardiovasculaires prouvés – Effet de<br />
classe ou effet de la chlorthalidone? 20 e Réunion<br />
scientifique annuelle de la société québécoise<br />
d’hypertension artérielle, Québec, Québec<br />
Modérateur – Symposium « Échange sur le diabète<br />
international », Montréal, Québec<br />
Active research in nephrology: refractory arterial<br />
hypertension, 9 th Annual Nephrology Educator Forum,<br />
Montréal, Québec<br />
Éric LÉCUYER<br />
Messenger RNA nuclear retention as a novel facet of the<br />
DNA damage response, 53 rd Drosophila Research<br />
Conference, Chicago, Illinois<br />
Tarik MÖRÖY<br />
Growth factor independence 1 (Gfi136N) predisposes to<br />
acute myeloid leukemia by including genome-wide<br />
epigenetic changes in oncogenes such as Hoxa9, 53 rd<br />
Annual Meeting of the American Society of<br />
Hematology, San Francisco, Californie<br />
Katrina PODSYPANINA<br />
Regulating oncogenes in mice to model cures in patients,<br />
23 e colloque de l’IFSBM : Environnement et cancer,<br />
Institut de cancérologie Gustave Roussy, Villejuif,<br />
France<br />
Rémi RABASA-LHORET<br />
Le but dans le diabète de type 2: contrôler la glycémie et le<br />
poids sans causer d’hypoglycémie, Symposium<br />
francophone de médecine (réalisation de médecins<br />
francophones du Canada), Montréal, Québec<br />
Symposium « Today on talk type 2: GLP-1 analogues,<br />
DPP-inhibitors and your type 2 diabetes patients », Family<br />
Medicine Forum, Montréal, Québec<br />
La prise en charge du diabète : les nouveautés et les<br />
avenues futures, Association Diabète Québec, Québec,<br />
Québec<br />
Activité physique et diabète de type 1 – Programme de<br />
recherche de l’<strong>IRCM</strong>, Congrès Diabète Québec, Québec<br />
Modérateur lors du Congrès Diabète Montréal, Montréal,<br />
Québec<br />
Should we introduce insulin before cystic fibrosis related<br />
diabetes diagnosis? Canadian Respiratory Conference<br />
“A Breath of Fresh Air”, Vancouver, Colombie-<br />
Britannique<br />
Understanding the role of GLP-1 agonists in type 2<br />
diabetes, Cardio-Metabolic Summit, Montréal, Québec<br />
When metformin is not enough: How to choose a second<br />
agent? Cardio-Metabolic Summit, Montréal, Québec<br />
Insulin sensitive vs insulin resistant obesity, European<br />
Group for the Study of Insulin Resistance (EGIR)<br />
Meeting <strong>2012</strong>, Lyon, France<br />
François ROBERT<br />
A universal RNA polymerase II CTD cycle is orchestrated<br />
by complex interplays between kinase, hosphatase and<br />
isomerase enzymes along genes, CSH Meeting on<br />
Mechanisms of eukaryotic transcription,Cold Spring<br />
Harbor, New York<br />
Peter W. SCHILLER<br />
Bifunctional peptides with a µ/δ opioid activity profile as<br />
analgesic drug candidates with reduced side effects, 12 th<br />
Chinese International Peptide Symposium (CPS-<strong>2012</strong>),<br />
Shenyang, Chine<br />
Nabil G. SEIDAH<br />
Is reduction of PCSK9 levels a promising therapy for<br />
atherosclerosis?: in vivo models and novel approaches to<br />
silence PCSK9, National Atherosclerosis Forum,<br />
Montréal, Québec<br />
Novel insights into the physiological functions of the<br />
proprotein convertases, 7 th General Meeting of the<br />
International Proteolysis Society, San Diego, Californie<br />
The physiological roles of PCSK9 and its targeting<br />
strategies for lipid lowering, Workshop on Novel lipidlowering<br />
strategies, XVI International Symposium on<br />
Atherosclerosis, Sydney, Australie<br />
61